New framework agreement focuses on a loan repayment plan, allowing the pharmaceutical firm to refocus on its core CNS pipeline.
The unsolicited offer represents a 53% premium, as Mobix escalates its takeover attempt for the semiconductor firm.
Deal with Deriva Energy expected to be immediately accretive, boosting renewable energy assets and targeting a cash available for distribution (CAFD) yield over 12%.
The merger signals accelerating consolidation within the U.S. regional banking sector, creating the nation's 9th largest bank.
The deal will see the Singapore-based social technology company list on the Nasdaq, valuing the combined entity at approximately $300 million.
The marketing application for AVT23, a biosimilar to the multi-billion dollar asthma drug Xolair, marks a key regulatory step for Alvotech in the European market.
First patients implanted with the novel neurostimulator marks a key step in challenging market leader Inspire Medical after recent FDA approval.
The designation for ALTO-101 targets cognitive impairment, a debilitating condition with no currently approved treatments, signaling a major regulatory milestone.